Abstract:Lung cancer is the leading cause of cancer death worldwide and lung adenocarcinoma (LUAD) accounts for most of these cases. Despite impressive advances in LUAD biology and new therapies, 5-year survival from stage-IV LUAD remains dismal (<10%), and improving LUAD outcomes represents a major, urgent, unmet medical need. Current LUAD therapeutics include "conventional" (chemoradiation), "targeted", and "immune" (e.g., checkpoint inhibitor) agents. These modalities improve patient outcomes, but they are far from panaceas. Chemoradiation and targeted therapies extend survival, but disease inevitably recurs owing to multiple resistance mechanisms. Immune therapies can cure other malignancies (e.g., melanoma), but only some LUAD patients respond, and even they are not cured. Combinations of conventional, targeted, and immune therapies will probably be needed to cure most, if not all, advanced LUAD patients, and cure of LUAD (or any malignancy) likely requires generation of a durable anti-tumor immune response. Hence, to optimally deploy any conventional or targeted agent, we must understand its effects on cancer cells and cells in the tumor microenvironment (TME). To this end, we developed unique genetically engineered mouse models (GEMMs) to interrogate the cancer cell-autonomous and non-autonomous actions of the protein-tyrosine phosphatase SHP2 (encoded by Ptpn11) and SHP2 inhibitors (SHP2is) in Kras-mutant (Kras G12D ;Trp53 -/-, "KP") LUAD. These include mice with cell-specific expression of an SHP2i resistant Ptpn11 mutant (Ptpn11 P491Q ) or cell-specific Ptpn11 f/f deletion. Perhaps surprisingly, neither deletion of SHP2 in T cells nor inability of SHP2i to act in T cells affected KP LUAD growth. Instead, we found that metastatic KP LUAD is associated with tumor-promoting, phenotypic and functional "B-regulatory cells" (Bregs) in the TME and draining lymph nodes (LNs). Genetic and cell culture experiments indicate that mutant KRAS, by evoking secretion of specific factors, induces Breg development from naïve splenic B cells. Remarkably, SHP2i, acting directly in B cells, blocks Breg development in vitro and in vivo. Moreover, B cell-specific Ptpn11-KO has direct anti-tumor effects. Flow cytometry and immunostaining studies revealed Breg cell expansion in tumor-infiltrated mediastinal lymph nodes (meLNs), accompanied by altered lymph node architecture and altered distribution of B cells between tumors and draining meLNs. Treatment with SHP2i or selective Ptpn11 deletion in B cells restored meLN integrity, even in the presence of KP tumor cell infiltration, and rebalanced B cell distribution. Studies with cell-specific drug resistant mice show that SHP2i action in B cells is required for these effects. Our results provide new insight into the role of tumor-associated B cells and SHP2i in KRAS mutant lung cancer and provide an experimental framework for deconvolving the compartment-specific effects of other targeted therapies in the TME. Citation Format: Benjamin G Neel, Yi Ban, Yingzhuo Liu, Kwok-kin Wong. Deconvolving the cell-specific actions of SHP2 inhibitors in the lung cancer tumor microenvironment reveals requirement for SHP2 in B-regulatory cell development [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A018.

SHP2 Contributes to Resistance of KRAS P.g12c-Driven Lung Cancer Cells to MRTX849 by Regulating Β-Catenin/c-myc Axis.

Repotrectinib Increases KRAS-G12C Inhibitor Effectiveness Via Simultaneous Inhibition of SRC, FAK, and JAK2

SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity

SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

High SHP2 expression determines the efficacy of PD ‐1/ PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer

Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC

SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness

Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade

SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition

Shp2 Regulates Migratory Behavior and Response to EGFR-TKIs Through ERK1/2 Pathway Activation in Non-Small Cell Lung Cancer Cells

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors

Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways

Abstract 2679: Synergistic Effects of the Combination of Kras (G12C) with SHP2, ERK 1/2, Mtorc1/2 or XPO1 Inhibition for the Treatment of Kras (G12C) Mutated Cancer

Abstract B093: Treating KRAS(G12D) inhibitor resistance using a KRAS- and HSP90 chaperone-targeted hetero-bispecific small molecule agent

Abstract 1943: Discovery and characterization of potential drivers of resistance to the KRAS G12D inhibitor, MRTX1133, in cancer cell line models

Abstract 5733: Combining KRASG12C(ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer

Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer

Combining RAS (ON) inhibitor with SHP2 inhibition sensitises immune excluded lung tumours to immune checkpoint blockade: a strategy for turning cold tumours hot

JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers

Abstract A018: Deconvolving the cell-specific actions of SHP2 inhibitors in the lung cancer tumor microenvironment reveals requirement for SHP2 in B-regulatory cell development